Claris Bio
PrivateLast Round
Series B
Jul 28, 2026
Est. Valuation
$188M
Total Funding Raised
$175M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Claris Bio operates in Healthcare & Life Sciences and is based in Jersey City, New Jersey. Its latest recorded funding round was a Series B round in July 2026.
Claris Bio is a biotechnology company that specializes in the development of topical formulation technology for the treatment of orphan ophthalmic disorders and corneal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Claris Bio Comparables
Compare Claris Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iView Therapeutics | 86% | |
| Selagine, Inc. | 82% | |
| Stellular Bio | 81% |
For institutional investors. Book with your work email.
Claris Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 28, 2026 | ||||
| Series A | Jan 4, 2024 |
For institutional investors. Book with your work email.
Claris Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B, Series A |
| RA Capital Management | Series A |
| Mass General Brigham Innovation | Series B, Series A |
| Catalio Capital Management | Series B |
| Novo Holdings | Series B, Series A |
| Aisling Capital | Series B |
| Adage Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 125% MoM, reaching 3.5K.
- Aug 20, 2026
Grew 80% QoQ, from 10 to 18 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- closes_offices_inSep 29, 2026
Claris Bio is relocating its corporate headquarters from New Jersey to California, with the new South San Francisco location becoming official in Oct '26.
- is_developingSep 25, 2026
Claris Bio prepares CSB-001 (oremepermin alfa ophthalmic solution) for pivotal studies in patients with limbal stem cell deficiency, which are planned to begin in H1 '27.
For institutional investors. Book with your work email.
Claris Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Claris Bio's valuation, stock price, and market status.
Is Claris Bio a public or private company?
Claris Bio is a private company.
What is the current stock price of Claris Bio?
Claris Bio is a private company, so its shares have no public market price. Caplight tracks Claris Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Claris Bio worth (valuation)?
Claris Bio's valuation is estimated at $188.0M based on funding round data.
Can I buy Claris Bio stock?
Claris Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Claris Bio's last funding round?
Claris Bio's most recent funding round was Series B on July 28, 2026.
Who are the main investors in Claris Bio?
Key investors in Claris Bio include Catalio Capital Management, Samsara BioCapital.
Will Claris Bio IPO soon?
No public IPO plans have been announced for Claris Bio.
How can I track Claris Bio secondary market activity?
Caplight tracks bids, offers, and trades in Claris Bio's shares on secondary markets.